Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)
In: Thomson Reuters ONE, 2022-08-17
Zeitungsartikel
Zugriff:
(GLOBE NEWSWIRE via COMTEX) -- Phase 1b clinical trial (ACTION) designed to evaluate TT11 as a potential second-line therapy TT11, Tessa's autologous CD30-CAR-T therapy, is also being investigated as a [...]
Titel: |
Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)
|
---|---|
Zeitschrift: | Thomson Reuters ONE, 2022-08-17 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|